Alnylam Pharmaceuticals is gaining traction as investors respond positively to its advancements in Alzheimer's treatment.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is rising today, up 3.11% to close at CA$251.92. The stock's uptick comes amid increased attention on Alzheimer's disease therapies, particularly as the company advances its innovative RNA interference (RNAi) treatments.
Investor takeaway: Investors are optimistic about Alnylam's potential to address unmet needs in Alzheimer's treatment, bolstered by recent clinical data and market trends favoring RNA-based therapies.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$32.06B
P/E
41.7x
52W high
$495.55
52W low
$197.81
1W change
-2.27%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 52.0% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+52.0% Upside
Current Price
C$244.32
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
44.9%
Annualized
90-Day Vol
79.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$204.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$230.20 | C$197.15 – C$268.79 |
| 60 trading days | C$216.90 | C$174.21 – C$270.05 |
| 90 trading days | C$204.36 | C$156.26 – C$267.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
3.11% Increase in Stock Price
Alnylam's stock price reflects growing investor confidence in its Alzheimer's treatment pipeline, particularly as the global RNA interference therapeutics market is projected to reach USD 31.4 billion by 2035.
Bull case
Alnylam is making significant strides with its RNAi therapies, especially mivelsiran for Alzheimer's. This positions the company well in a growing market, offering the potential for substantial revenue as the demand for effective treatments rises.
Bear case
Despite its promising pipeline, Alnylam faces challenges like pricing pressures and competition in the Alzheimer's treatment space. These factors could affect its market share and profitability.
Advertisement
Market Response to Alzheimer's Treatment Advances
Alnylam's recent focus on Alzheimer's therapies has garnered attention as the company advances its mivelsiran candidate, which aims to lower amyloid precursor protein levels. This approach could potentially slow the progression of Alzheimer's disease, a condition that affects millions globally. The positive clinical data released recently has fueled investor optimism, contributing to the stock's rise.
Growing Demand for RNA-Based Therapies
The global RNA interference therapeutics market is expected to reach USD 31.4 billion by 2035, driven by advances in genetic research and the rising prevalence of chronic diseases. Alnylam's positioning as a leader in RNA-based medicines places it at the forefront of this expanding market, making it a compelling investment opportunity for those looking to capitalize on the biotech sector's growth.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
